Edition:
United Kingdom

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
20 Jul 2018
Change (% chg)

$0.04 (+3.12%)
Prev Close
$1.28
Open
$1.27
Day's High
$1.32
Day's Low
$1.27
Volume
53,663
Avg. Vol
125,484
52-wk High
$2.95
52-wk Low
$0.88

Chart for

About

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid... (more)

Overall

Beta: 2.92
Market Cap(Mil.): $22.01
Shares Outstanding(Mil.): 21.17
Dividend: --
Yield (%): --

Financials

  ONCS.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.15 -- --
ROI: -105.93 2.22 14.61
ROE: -110.71 3.86 16.34

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

08 May 2018

BRIEF-Oncosec Medical Says Board Determined To Consolidate Roles Of CEO And President

* ONCOSEC MEDICAL INC - BOARD DETERMINED TO CONSOLIDATE ROLES OF CHIEF EXECUTIVE OFFICER AND PRESIDENT

04 May 2018

BRIEF-Oncosec Medical Prices $20 Mln Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-OncoSec Medical Announces Proposed Public Offering Of Common Stock

* ONCOSEC MEDICAL INCORPORATED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

31 Jan 2018

Earnings vs. Estimates